Genomic Valley Biotech Ltd Management Discussions

In compliance of Regulation 34(3) and 54(f) read with Schedule V of Securities Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find Management Discussion and Analysis Report forming part of Annual Report.

1. OVERVIEW OF THE BUSINESS

Present Status

The Company is providing consultancy in the Horticultural and Agricultural products. The company is also trading in Horticultural and Agricultural products. The company is also adding activities in Human Genomics.

Economy and Markets

India is among the top 12 destinations for biotechnology worldwide. The Department of Biotechnology (DBT), under the Ministry of Science and Technology, has placed great emphasis on developing an ecosystem for the development of excellence and research in a variety of biotechnology fields in India.

By creating and using a variety of tools at its disposal, such as vaccines, antivirals, diagnostic tests, and other tools, the biotechnology industry has been at the forefront of the fight against the Covid-19 pandemic. The pandemic has assisted the country in setting up the ideal ecosystem for production, sourcing, and exporting medical devices and vaccines.

Indias bio-economy industry has grown from US$ 10 billion in 2015 to US$ 130 billion in 2024. Indias bioeconomy contributes 2.6% to Indias GDP, as of 2021. Indias bioeconomy is poised to reach US$ 300 billion by 2030.

Nearly a fifth of Indias bioeconomy, standing at US$ 14.56 billion, was due to the Covid-19 vaccination and testing drive. Covid-19 vaccines had a worth of US$ 8.7 billion, whereas testing cost US$ 5.9 billion. 1.45 billion Covid-19 doses were administered in 2021, and 1.3 million Covid tests were taken every day.

The largest portion of the Indian bioeconomy continues to be accounted for by biopharma. Biopharma accounted for 49% share of the bioeconomy, and its total economic contribution was estimated at US$ 39.4 billion. By 2025, the vaccination market in India is projected to be worth Rs. 252 billion (US$ 3.04 billion). In July 2022, Indias 1st indigenously developed quadrivalent Human Papilloma Virus (qHPV) vaccine against Cervical cancer supported by DBT and BIRAC received market authorization from DCGI.

Industry Structure and Development

As you all know Honorable Prime Minister Shri Narendra Modi had explicitly stated in his election campaign that farmers would be the priority and the government would ensure they got 50% returns over their total costs. Keeping this in mind your company has started implementing measures to provide all round support to ensure a minimum return and also increase their production and earning multi-fold.

A Asri Farming Consultancy:

With the expert team of agriculturists and other technical people, the company is also providing Agri Farming Consultancy to farmers and other clients on case - to - case basis. This way company is providing solutions to problems being faced by the HNI clients in agri-farming business as per their specific needs.

The Companys Agri Consultancy services aim to transform the agricultural sector by providing expert guidance and innovative solutions to address key challenges. Catering to farmers, agribusinesses, and policymakers, these services focus on enhancing productivity, sustainability, and profitability in agricultural practices.

The Company provides expert consultancy in high-tech cultivation techniques, enabling farmers and agribusinesses to adopt advanced agricultural practices for enhanced productivity and sustainability. These include environment- controlled polyhouses, which create optimal growing conditions by regulating temperature, humidity, and light, ensuring year-round cultivation with protection from adverse weather and pests. The consultancy also specializes in Nutrient Film Technique (NFT), a hydroponic method where a thin film of nutrient-rich water flows over plant roots, promoting efficient nutrient absorption and faster growth, ideal for leafy greens and herbs. Additionally, the Deep Flow Technique (DFT) offers a hydroponic system for larger crops like tomatoes and cucumbers, with roots submerged in nutrient-rich water for consistent nourishment. By leveraging these innovative techniques, the Company empowers clients to achieve higher yields, superior quality, and resource-efficient farming practices, catering to both domestic and export markets.

Key areas of focus include:

- Sustainable Farming Practices: Promoting eco-friendly methods that enhance soil health, conserve resources, and build resilience to climate change.

- Precision Agriculture: Employing advanced technologies like GPS mapping, satellite imagery, and IoT devices to optimize crop management and reduce waste.

- Resource Optimization: Offering strategies to maximize water, fertilizer, and input efficiency to achieve higher yields with minimal environmental impact.

- Agri-Tech Integration: Advocating the use of drones, robotics, and automation to modernize farming processes and increase operational efficiency.

The Company also provides personalized Agri Farming Consultancy through its team of expert agriculturists and technical professionals. These tailored solutions address the specific needs of clients, including High Net Worth Individuals (HNIs) involved in agri-farming businesses. By understanding their unique challenges, the Company delivers impactful, customized strategies that drive superior results and align with client objectives.

In addition to direct consultancy services, the Company plays a proactive role in knowledge sharing and capacity building by organizing workshops, seminars, and training programs. These initiatives are designed to educate farmers and stakeholders about the latest advancements in agricultural practices and technologies, empowering them to adopt innovative solutions effectively. This commitment to skill development further enhances the impact of the Companys efforts, fostering a culture of continuous improvement and innovation in the agricultural sector.

Through its comprehensive Agri Consultancy services, the Company empowers stakeholders with actionable insights and advanced tools, fostering long-term sustainability and economic growth. These efforts also contribute to environmental conservation, enabling the agricultural sector to evolve and thrive in a rapidly changing world.

B. Human Genomics: Advancing Personalized Healthcare:

The company intends to develop full packaging system and logistics to deliver fruits and vegetable direct to homes in NCR as per their daily demands and orders. The company is also working on to make it an online portal and also through mobile app to reach the masses and thus gathering increase orders and reach to more and more households. Thus, eliminating of middle man will reduce the cost and enhance the quality of fruits and vegetables.

The Company is a trailblazer in the field of Human Genomics, driving innovation in genetic research and personalized healthcare. By leveraging cutting-edge technologies such as Next-Generation Sequencing (NGS) and artificial intelligence (AI), the Company is addressing critical healthcare challenges and transforming patient care. This dynamic domain focuses on using advanced genomic and bioinformatics tools to enable early diagnosis, targeted therapies, and improved health outcomes.

Key offerings in this area include :

- Genetic Testing and Analysis : Comprehensive genetic profiling is conducted to uncover valuable insights into individual health risks and hereditary predispositions. By utilizing NGS technologies, the Company delivers accurate and detailed assessments that empower individuals and healthcare providers to make informed decisions about preventive and therapeutic measures.

GENOMIC VALLEY BIOTECH LIMITED

31 st ANNUAL REPORT 2024-25

- Disease Screening and Prediction: The Companys expertise enables the early detection and prevention of genetic disorders and complex diseases such as cancer, diabetes, and cardiovascular conditions. With advanced screening capabilities, individuals are provided with critical information to address potential health challenges proactively, significantly improving long-term outcomes.

- Tailored Treatment Planning: By analyzing genomic data, the Company develops highly personalized treatment strategies. This approach is particularly impactful oncology, where precision medicine is essential for targeting specific genetic mutations. These tailored plans minimize adverse effects and maximize the effectiveness of therapies, setting a new standard for patient care.

- Bioinformatics Solutions: Leveraging powerful computational tools, the Company analyzes and interprets vast amounts of genomic data to unlock insights that drive both clinical applications and research innovation. This expertise ensures that the latest advancements in genomics are seamlessly integrated into healthcare practices, benefiting both researchers and practitioners.

Beyond its technical capabilities, the Company offers a comprehensive approach to empowering individuals and healthcare providers. Genetic counseling services help patients understand their genetic makeup and its implications for health and wellness. By fostering a deeper awareness of genomics, the Company plays a vital role in bridging the gap between cutting-edge science and practical, everyday healthcare solutions.

In addition to patient-focused services, the Company is actively involved in advancing research and contributing to global efforts to combat genetic disorders and complex diseases. Its contributions to precision medicine have positioned the Company as a leader in this rapidly evolving field, with a reputation for delivering high-quality, impactful solutions.

Furthermore, the Company invests in educational initiatives such as workshops and training programs to share its expertise with healthcare professionals, researchers, and academic institutions. By doing so, the Company not only enhances the capabilities of its partners but also strengthens its leadership in the genomics space.

C. Future Activities

1. Human Genomics and Precision Medicine:

o To advance research in human genomics to identify genetic variations and biomarkers associated with diseases.

o To develop personalized medicine strategies by leveraging AI-integrated genomic data analysis for better diagnosis and treatment.

o To enhance healthcare outcomes through genetic predisposition analysis and pharmacogenomics for personalized drug recommendations.

2. Plant Genomics for Sustainable Agriculture:

o To utilize genomic techniques for improving crop yield, resistance to diseases, and adaptation to environmental stresses.

o To integrate AI-based bioinformatics tools in plant genomics for efficient trait mapping and gene editing solutions.

o To collaborate with agricultural biotechnology firms to innovate sustainable and climate-resilient farming technologies.

3. Microbial Genomics and Metagenomics:

o To study microbial genomes and their applications in health, agriculture, and environmental sustainability.

o To advance metagenomic research to understand the human microbiomes role in health and disease, enabling the development of microbiome-based diagnostics and therapeutics.

o To promote microbial biotechnology for industrial applications such as bioremediation, fermentation, and biofuel production.

4. Strategic Partnerships:

o Signed an agreement with Artemis Hospital Gurgaon to leverage their state-of-the-art lab facilities for Next-Generation Sequencing (NGS) analysis.

o This collaboration enhances the precision and efficiency of genomic research and diagnostic services, supporting advancements in personalized medicine and cutting-edge genetic studies.

o In the later part, we will build an in-house state-of-the-art wet-lab facility for NGS and Molecular

Genetics for enhanced and timely data output and support. We would like to collaborate as a B2B partnership as well as a B2C approach for enhanced customer support for their analysis needs.

5. Bioinformatics and AI-Driven Genomic Solutions:

o To develop proprietary bioinformatics tools and software for genomic data analysis, visualization, and interpretation.

o To leverage AI and machine learning for accelerating genomic research and improving diagnostic accuracy.

o To create robust platforms for managing large-scale genomic datasets and facilitating global research collaborations.

6. Expanding Personalized Care Through Genetic Counseling:

o Comprehensive Genetic Counseling Services: Led by our esteemed Genetic Counselor and Consultant, these services help patients understand their genetic risks and plan preventive measures.

o Tailored Support for Diverse Needs: From assessing hereditary risks and managing rare diseases to exploring family planning options, our sessions provide personalized guidance for every individual.

o Empowering Informed Decisions: Our counseling ensures patients have the clarity and support needed to make well-informed decisions about their health and future.

7. Genomic Profiling and Ayurvedic Lifestyle Associations in Chronic Kidney Disease (CKD) in Gariaband, Chhattisgarh:

o Understanding Genetic Susceptibility: Identify and analyze genetic markers linked to CKD to provide individuals and families with insights into hereditary risks and potential preventive strategies.

o Tailored Interventions for Affected Populations: Offer specialized counseling and personalized healthcare plans based on genomic and environmental data to address CKD prevalence effectively.

o Empowering Communities with Knowledge: Educate communities and healthcare providers about CKD-related genetic factors, enabling early detection and informed decision-making for better health outcomes.

8. Community Health and Genomic Initiatives:

o To implement population-wide genetic screening programs for early disease detection and public health improvement.

o To design community health initiatives informed by genomic data to address region-specific health challenges.

o To educate and empower healthcare providers and the public on the benefits of genomic medicine.

9. Extramural and Collaborative Research:

o To participate in and support national and international research projects in genomics and biotechnology.

o To foster partnerships with academic institutions, research organizations, and industry leaders for mutual advancement in genomic sciences.

o To actively contribute to global efforts in genomic data sharing and standardization.

10. Innovation Hub for Biotechnology and Genomics:

o To establish GVBL as a global epicenter for genomics and biotechnology innovation inspired by the vision of creating a Silicon Valley of genomics in India.

o To create a multidisciplinary platform integrating genomics, AI, and IT for advancing healthcare, agriculture, and industrial biotechnology.

o To provide Research Process Outsourcing (RPO) services to support and accelerate global genomic research efforts.

11. Pharmaceutical Genomics and Biomanufacturing:

o To pioneer the integration of genomics in pharmaceutical development for targeted therapies.

o To establish scalable and efficient biomanufacturing processes for producing biologics and gene therapies.

o To contribute to global drug discovery efforts through genomic insights and AI-driven methodologies.

12. Research and Development:

o To lead innovations in all areas of human genomics, with a specific focus on identifying novel genetic biomarkers and therapeutic targets in oncology.

o To integrate Next-Generation Sequencing (NGS) with AI for rapid, precise, and cost-effective oncology diagnostics.

o To establish strategic collaborations with academic and industry leaders for translational cancer research.

13. Radiogenomic Innovations in Cancer Diagnosis and Treatment :

o Lead advancements in radiogenomics by integrating imaging and genomic data to enhance cancer diagnosis and personalized treatment strategies.

o Identify novel genetic biomarkers and therapeutic targets through radiogenomic analysis, with a specific focus on improving precision in oncology.

o Develop machine learning-driven models to correlate radiological features with genetic mutations, facilitating early detection and accurate classification of cancer subtypes.

o Create robust, user-friendly applications for clinical use, enabling healthcare providers to access predictive insights and optimize patient care.

D Biotechnology Industry Growth

The growth of Biotechnology industry as per Transparency Market Research is estimated to observe substantial growth during 2010 and 2018 as investments from around the world are anticipated to rise, especially from emerging economical regions of the world. The report states that the global market for biotechnology, studied according to its application areas, shall grow at an average annual growth rate of CAGR 11.6% from 2012 to 2018 and reach a value worth USD 414.5 billion by the end of 2018. This market was valued approximately USD 216.5 billion in 2011. The market of bio agriculture, combined with that of bio seeds, is projected to reach a value worth USD 40.50 billion by 2024. The field of biopharmaceuticals dominated the global biotechnology market and accounted for 60% shares of it in the year 2011. Many biotechnological industries flourished by the technological advancements leading to new discoveries and rising demands from the pharmaceutical and agricultural sectors.

2. OPPORTUNITY AND THREATS

AGRICULTURE:

- Supply chain infrastructure

Technology-driven, integrated supply chains enable entities to reduce inventory and costs, add product value, extend resources, accelerate time to market, expand market, increase pricing for sellers and variety for buyers as well as retain customers. In order to have a successful supply chain, the Indian Government has sought to involve multiple stakeholders to improve interactions between farmers, processors, distributors and retailers. The nations processed food industry is expected to grow to US$ 958 billion by 2025 at a compound annual growth rate (CAGR) of 12%. The governments focus is on supply chain-related infrastructures like cold storage, abattoirs and food parks.

- Potential global outsourcing hubs

Huge opportunity exists for agri input segments like seeds and plant growth nutrients. According to the Center for Environment and Agriculture (CENTEGRO) and Crop Care Federation of India (CCFI), India can become the global agricultural hub for other countries, which have harsh weather, scarce labour and lands, and are seeking to outsource their agriculture. There is a huge opportunity for agri-input segments such as seeds and nutrients for plant growth. To establish GVBL as a global epicenter for genomics and biotechnology innovation inspired by the vision of creating a Silicon Valley of genomics in India. To create a multidisciplinary platform integrating genomics, AI, and IT for advancing healthcare, agriculture, and industrial biotechnology. To provide Research Process Outsourcing (RPO) services to support and accelerate global genomic research efforts.

- Farm management services

Given the importance of agriculture in India, both the government and private players are working to improve the efficiency and productivity of Indian agriculture and exploring how Farming as a Service (FaaS) solutions can play a role. FaaS seeks to provide affordable technology solutions for efficient

farming. It converts fixed costs into variable costs for farmers, thus making the techniques more affordable for a majority of small farmers. Its services are available on a subscription or pay-per-use basis in 3 broad categories, which are crucial across the agriculture value chain.

BIOTECHNOLOGY

Biotechnology is one of the "hot spots" in research and development in this century. Great chances and opportunities lie ahead, but also tremendous threats. While technology and knowledge is easily available all over the world, it can be quite difficult to access markets and to commercialize biotechnological products.

Biotechnology, regardless of red, green or white biotechnology, promises high profits. However, the field is also complex, fast moving and costly. Especially in the field of medical applications there are many risks associated with biotechnology. One example is a drug developed against multiple sclerosis, which had possible profits of 3$ billion.

After two patients developing a rare brain disease in clinical trials the profits vaporized and the stock market were in an uproar. Nevertheless, does the United Nations Development Program see "biotechnology innovation and globalization as a means of helping the poor of the world live fuller, richer and more secure lives". Only through commercialization this promise will come true. Commercialization is converting or moving technology into a profit making position.

In our opinion the most important point is to bridge the gap between technology and markets. The matching of technological challenge and market challenge is difficult and many tools have been developed to address this problem.

In the Interim Budget 2024-25, the Department of Biotechnology (DBT) was allotted Rs. 2,251.52 crore (US$ 271 million). India has potential for clinical trials due to a large and low-cost market. Clinical trials in India are regulated by the Central Drug Standard Control Organisation, which has reduced approval time to about 30-60 days, giving opportunity for market growth. Biofuels and bioenergy are considered alternative resources and are gaining popularity in India.

SUPPLY CHAIN

For providing diagnostics services for the Wet Lab, your company has the necessary understanding of the relevant companies and organizations for the purchase of the tissue culture production of your company.

Signed an agreement with Artemis Hospital Gurgaon to leverage their state-of-the-art lab facilities for Next- Generation Sequencing (NGS) analysis. This collaboration enhances the precision and efficiency of genomic research and diagnostic services, supporting advancements in personalized medicine and cutting-edge genetic studies. In the later part, we will build an in-house state-of-the-art wet lab facility for NGS and Molecular Genetics for enhanced and timely data output and support. We would like to collaborate as a B2B partnership as well as a B2C approach for enhanced customer support for their analysis needs.

Your Companys supply chain agenda remained focused on five key areas

1 . Customer service excellence,

2 . Consumer and customer quality,

3. End to end cash and cost savings program,

4. Leading with innovation, and

5. Technology and sustainability.

Your Company made significant progress in its vision to deliver customer service excellence to enable sustainable growth.

RESEARCH & DEVELOPMENT

To lead innovations in all areas of human genomics, with a specific focus on identifying novel genetic biomarkers and therapeutic targets in oncology. To integrate Next-Generation Sequencing (NGS) with AI for rapid, precise, and cost-effective oncology diagnostics. To establish strategic collaborations with academic and industry leaders for translational cancer research.

Our Research Team wishes to conduct Basic Research at the Premier Institute in the country in the following prospective fields:

Agriculture

- Crop Biotechnology

- Bio Fertilizers

- Bio Pesticides and Crop Management

- Plant Biotechnology

Plant Tissue Culture Micopropogation

- Bio prospecting and Molecular taxonomy

- Bio fuels

- Medicinal and Aromatic Plants

Medical Biotechnology

- Vaccines

- Diagnostic

- Drug Development

- Human Genetics and Genome Analysis

3. COMPETITION:

We operate in a competitive atmosphere with multiple few organized competitors and multiple unorganized customers. There are no entry barriers in our industry which puts us to the threat of competition from new entrants. There are numerous players operating in the industry. We face tough competition in our business from a large number of unorganized and a few organized players. We believe that we have the potential to compete effectively in the market with our quality of products. We believe that the principal factors affecting competition in our business include client relationships, reputation, and the relative quality and price of the products. We compete with these competitors to enter directly into deals with customers.

4. PROSPECT & OUTLOOK

We are excited to announce a strategic collaboration with Artemis Hospital Gurgaon through the signing of an agreement to leverage their state-of-the-art laboratory facilities for Next-Generation Sequencing (NGS) analysis. This partnership enhances the precision and efficiency of genomic research and diagnostic services, driving advancements in personalized medicine and cutting-edge genetic studies. Looking ahead, we plan to establish an in-house, state-of-the-art wet-lab facility for NGS and Molecular Genetics, enabling enhanced and timely data output to meet the growing demands of the field. This initiative supports a dual approach: fostering B2B partnerships for collaborative research and tailored solutions while strengthening B2C services to provide personalized support for individual analysis needs. Together, these efforts position us as a leading player in genomic and molecular research, contributing to significant advancements in healthcare and science.

Environment, safety, Health and Energy Conservation

Your Company has a vision of being a Zero Injury organization. The Compass, your Companys strategic framework, integrates Safety as a non-negotiable value. Over the past years, your Company has not reported and injuries across its operations.

This has been achieved through a combination of training and hardware upgradation leveraging core technology concepts and safety standards from the Company. Sustainability is deeply rooted in all the operations of your Company ranging from sourcing to Production and logistics. Your Companys aim is to achieve significant reduction in environmental impact of operations.

Your Company has used various majors for conservation of energy. Several efforts have been conferred by your Company in the spheres of Safety, Environment and Sustainability.

5. RISKS AND CONCERNS

There is a rich public debate about how the potential risks associated with biotechnology methods and bio industry products should be assessed and about whether and how bioethics should influence public policy. A general structure for guiding public policy discourse is emerging but is not fully developed. Groups perceive risks differently depending on their culture, scientific background, perception of government, and other factors. Expert opinion supports a range of positions. Deeply and honestly held but often conflicting beliefs and values about nature, animals, and the community good animate the debate. The result is that biotechnology issues are often highly contentious and debated on both scientific and ethical grounds. Two contemporary examples are:

?– Do human social benefits such as living a longer and leading more productive life due to biotechnology outweigh the harm that an animal or groups of animals must experience to produce those benefits.

?– Should an insurance company require information about an individuals genetic inheritance as a condition of eligibility for health insuranceRs

Biotechnologys risks are sometimes purely conjectural. Without research and clinical trials, risks cannot be fully assessed. Yet conjectural and ethical issues are important because biotechnology affects not only human practices and economic sectors, but also medical practices and the relationship between humanity, animals and the environment.

In Paul Thompsons view, [Biotechnology] is not simply another type of mechanical or chemical creation aimed at making the world better for us. In this instance, we are not simply reshaping matter, but are harnessing life. By manipulating life and natural evolution, we are taking the process that shaped our existence and that of every other living organism on the planet and restructuring it for our own benefit.

6. DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

The details of the financial performance of your Company are reflected in the Balance Sheet, Profit & Loss Account and other Financial Statements, appearing separately. Highlights are provided below:

(In Rs.)

Particulars	Standalone
	2025
Revenue from Operations	84,39,394
Other Income	44,660
Total Income	84,84,054
Profit/(Loss) Before Tax	44,14,376

The financial performance of your Company has been further explained in the Directors Report of your company for the year 2025, appearing separately.

7. ECONOMIC OUTLOOK

The long-term fundamentals of the Indian economy continue to be strong due to rising incomes and large investments. These growth drivers are expected to sustain over a long period of time. At the same time, there are some concerns due to uncertain global economic environment and slow recovery in developed markets.

8. HUMAN RESOURCES

The Company keeps developing its organizational structure consistently over time efforts are made to follow excellent Human Resource practices. Adequate efforts of the staff and management personnel are directed on imparting continuous training to improve the management practices. The objective of your company is to create a workplace where every person can achieve his or her potential. The employees are encouraged to put in their best. Lots of hard work is put in to ensure that new and innovative ideas are given due consideration to achieve the short and long term objectives of your company.

The employees are satisfied and having good relationship with management.

9. CAUTIONARY STATEMENT

Certain statements in the Management Discussion and Analysis describing your Companys views about the industry, expectations/predictions, objectives etc. may be forward looking within the meaning of applicable laws and regulations. Actual results may differ from those expressed or implied in these statements. Your Companys operations may, inter-alia, be affected by the supply and demand situations, input prices and availability, changes in Government regulations, tax laws, government or court decisions and other factors such as industry relations and economic developments etc. Investors should bear this in mind when considering the above statements.

Internal control system

The company has started it commercial activity. However, the management is having highly professional outlook at the adequate control system during all its commercial activities.